Please login to the form below

Not currently logged in
Email:
Password:

Indian court rejects Novartis patent demand

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

A court in the Indian city of Chennai has rejected a claim by the Swiss pharmaceutical company Novartis regarding its cancer drug, Glivec (imatinib).

Novartis was demanding that India grant a patent for Glivec to prevent cheap copies being made. The government in New Delhi opposed the move, saying that granting such a patent would violate India's patent legislation.

Novartis has been seeking a patent for Glivec in India, challenging the Indian patent law which currently does not protect incremental innovation. Indian law does not grant patents for modifications to old medicines, but only to properly innovative drugs developed after 1995.

6th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics